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Key Clinical Message
Recurrent lethal perinatal osteogenesis imperfecta may result from asymp-
tomatic parental mosaicism. A previously unreported mutation in COL1A2
leads to recurrent cases of fetal osteogenesis imperfecta Sillence type IIA, which
emphasizes the importance of clinical and genetic evaluation of mosaicism in
asymptomatic parents as verified mosaicism highly increases recurrence risk.
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Introduction
Osteogenesis imperfecta (OI), or brittle bone disease, is a
phenotypically and molecularly heterogeneous group of
genetic connective tissue disorders that occurs in one in
15,000–20,000 births [1]. The phenotypic appearance
ranges from minimal bone fragility, decreased bone mass,
blue sclerae, hyperlaxity of skin and ligaments, dentino-
genesis imperfecta, and hearing loss to severe bone mal-
formation and perinatal death caused by multiple
fractures [2]. Based on clinical characteristics, Sillence
et al. classified OI patients into four groups [3]. Labora-
tory testing for OI may include either biochemical testing
of collagen or, increasingly, next-generation sequencing
(NGS) of genes associated with OI. At present, 17 genes
associated with OI and closely related disorders have been
identified [4]. In 90% of cases, heterozygous mutations
in the COL1A1 or COL1A2 genes, encoding the alpha 1
and alpha 2 chains of collagen type I, respectively, are
responsible for the phenotype [5]. Collagen type I is the
most abundant protein of skin, bone, and tendon extra-
cellular matrices. The nondeforming OI (Sillence type I)
is related to quantitative deficiency of structurally normal
collagen, whereas lethal OI (type II), progressively
deforming (type III), and common variable (type IV)
mainly result from mutations that alter the collagen
structure [1]. COL1A1- and COL1A2-related OI are
inherited in an autosomal dominant manner. For OI
types II-IV, the intertwining of mutated and normal col-
lagen type I chains results in production of abnormal col-
lagen type I protein, which is rapidly degraded,
explaining the dominant negative effect of the mutations
[4]. A number of genes, including but not restricted to
cartilage-associated protein (CRTAP) and prolyl-3-hydro-
xylase-1 (P3H1, encoded by the LEPRE1 gene), have
recently been identified to be involved in autosomal
recessive OI. Thus, advances in molecular diagnostics
have identified new OI subtypes [6].
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Severe and perinatal lethal OI can be classified as Sil-
lence type II, (OMIM #166210). The condition may be
detected by an abnormal ultrasound scan around
20 weeks of gestation. The fetus presents with growth
retardation, shortening, and bowing of long bones which
are severely under-modeled and crumbled [4]. Multiple
fractures of the ribs leads to a beaded appearance of the
ribs (Sillence type IIA) or ribs can be thin (Sillence type
IIB) [4]. The postnatal presentation includes multiple
fractures, small thorax, decreased ossification of the skull,
and respiratory distress [7]. More than 60% of affected
infants die within the first day, and survival beyond
1 year is extremely rare [2].
Children with autosomal dominant inherited osteogen-
esis imperfecta may be born from unaffected parents due
to parental mosaicism [8–12]. We present a family in
which a case of lethal perinatal OI, Sillence type IIA, in a
fetus lead to the discovery of parental mosaicism for a
previously unreported synonymous mutation, c.
1863G>A, p.Lys621Lys in the COL1A2 gene presumed to
affect correct mRNA splicing. The fetus in the consecutive
pregnancy was also affected. The study emphasizes the
importance of clinical and genetic assessment for parental
mosaicism as this strongly influences recurrence risk.
Methods
Genetic analysis
DNA was isolated from the different specimens by stan-
dard methods. The entire coding and exon flanking
sequences of COL1A1 (NM_000088.3) and COL1A2
(NM_000089.3) were amplified by means of a custom
designed AmpliSeq capture assay, using the Ion Ampliseq
Lib 2.0 assay (Thermo Fisher Scientific, Waltham, USA).
Sequence-ready libraries were generated on the IonChef
and subsequently sequenced on the IonPGM (Thermo
Fisher Scientific, Waltham, USA) using HiQ chemistry on
a 318v2 chip (Ion PGMTM IC 200 Kit, Waltham, USA).
All procedures were carried out according to the manu-
facturer’s description (Thermo Fisher Scientific). Samples
were sequenced to a minimum mean depth of 500x.
Areas with low coverage (<30x) were Sanger sequenced.
Variants were filtered against the UCSC common SNP
panel (SNP142), and subsequent variants were manually
curated and confirmed by standard Sanger sequencing
(primers and PCR conditions are available upon specific
request).
The level of mosaicism is expressed as allele frequencies
determined directly from the next-generation sequencing
data. The sequencing depth of the c.1863 position was
1043, 876, and 883 in DNA isolated from blood, buccal,
and saliva cells, respectively.
Bone parameters
Areal bone mineral density (aBMD) was measured at the
lumbar spine, hip region, wrist, and whole body using
dual energy X-ray absorptiometry (DXA) (Hologic
Discovery, Waltham, MA). T-scores were calculated using
the reference range provided by the manufacturer and the
Third National Health and Nutrition Examination Survey
reference [13].
A high-resolution peripheral quantitative computed
tomography (HR-pQCT) system (XtremeCT, Scanco
Medical AG, Br€uttisellen, Switzerland) was used to assess
bone geometry, volumetric bone mineral density (vBMD),
and microarchitecture of radius and tibia in left and right
extremities. The default protocol for in vivo imaging was
applied providing a 9.02 mm axial 3D bone representa-
tion at each site. The offset from the endplate to the mea-
surement region was 9.5 and 22.5 mm at the distal radius
and tibia, respectively, with the scan region extending
proximally. Each scan consisted of 110 parallel CT slices
resulting in an 82 lm isotropic voxel size. Attenuation
data were converted to equivalent hydroxyapatite (HA)
densities, and measures of total, cortical, and trabecular
microarchitecture were computed using the standard
manufacturer’s software [14]. A phantom was scanned
daily for quality control (QRM, M€ohrendorf, Germany).
Standardized algorithms were used to separate the bone
into cortical and trabecular compartments, and calculate
trabecular bone volume per tissue volume (BV/TV), tra-
becular number (Tb.N), trabecular thickness (Tb.Th), and
trabecular spacing (Tb.Sp) as previously described [15].
Biochemical evaluation
Biochemical evaluation was performed with automated
techniques in an accredited laboratory including use of
liquid chromatography–mass spectrometry (LC-MS) tech-
nique and Architect c16000 (Abbott Diagnostics).
Results
Clinical report
A healthy, nonconsanguineous couple, who previously
gave birth to a healthy daughter, family pedigree shown
in Figure 1, was referred to genetic counseling after ter-
mination of a pregnancy at 19 weeks of gestation due to
a clearly abnormal ultrasound scan showing growth
restriction and a small thorax leading to suspicion of tha-
natophoric dysplasia. The aborted fetus was initially
assessed for thanatophoric dysplasia by direct sequencing
of the coding regions of the FGFR3 gene, but no muta-
tions were detected. Pathological examination of the fetus
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showed growth retardation, an abnormally shaped head,
shortening and bowing of the long bones, fractures of the
femora, decreased ossification of the skull, multiple rib
fractures of different ages, and very soft bone tissue in
accordance with the clinical phenotype OI. Radiograph of
the aborted fetus is shown in Figure 2. Mutational analy-
sis on fetal DNA revealed that the aborted fetus was
heterozygous for a synonymous variant c. 1863G>A,
p.Lys621Lys in the COL1A2 gene, Sanger sequencing
shown in Figure 3. The variant has, to our knowledge,
not been previously described and is accordingly not
reported in the Human Gene Mutation Database [16], in
the COL1A2 locus database (https://oi.gene.le.ac.uk/
home.php?select_db=COL1A2), or in the Exome Aggrega-
tion Consortium (ExAC) database. The variant does not
result in an amino acid change, but affects the last
nucleotide of exon 31, which according to in silico pre-
diction tools destroys the 50 splice site.
The mutation was not detected in full blood-derived
DNA from the mother. In a full blood-derived DNA sam-
ple from the father, the variant was detected with an allele
frequency of 33%, which lead to mutational analysis of
his parents. The variant was, as expected, not present in
full blood-derived DNA from the parents. Hence, the
mutation is likely a result of a postzygotic de novo event
in the father. Based on the clinical findings, in silico pre-
dictions, and the fact that it is a de novo event, the variant
was categorized as pathogenic and causal for the fetal
phenotype. The mosaic nature of the mutation was con-
firmed as DNA analysis on buccal cells and cells from
saliva revealed mutant allele frequencies of 19% and 33%,
respectively. The mother became pregnant again, and a
chorion villus biopsy was taken at 12 weeks of gestation.
Figure 1. Family pedigree.
Figure 2. Radiograph of the first aborted fetus at 19 weeks of
gestation showing shortening and bowing of the long bones, fractures
of the femora, decreased ossification of the skull, and multiple rib
fractures of different ages in accordance with the clinical phenotype OI.
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Mutation analysis of chorion villus DNA showed that this
fetus was heterozygous for the same mutation in the
COL1A2 gene and the pregnancy was subsequently termi-
nated. No detailed pathological examination was per-
formed, but the fetus at 15 weeks of gestation, was small
for gestational age, and presented postpartum with clear
clinical signs of OI in the form of narrow chest and short
and bowed extremities. In both OI pregnancies, ultra-
sound scans at 12 weeks of gestation were reported as
normal.
Phenotype of case with OI mosaicism
The father, age 34, had lived an active, healthy life. Clinical
examination showed normal height, normal sclerae, nor-
mal dental status, and normal configuration of extremities.
Neither chest wall deformities nor joint hypermobility or
hyperlaxity of the skin was observed. The only abnormal
finding was unilateral difference in the size of the
extremities as the left arm and leg were of smaller size
compared to extremities on the right side, shown in Fig-
ure 4. The left arm was 0.5 cm shorter than the right arm,
and the left hand was 0.5 cm shorter than the right hand.
The difference in leg length was 1.5 cm. He had a history
of fractures of the clavicular, scaphoid, and metatarsal
bones, which were related to high-energy trauma.
Standard DXA assessment of the lumbar spine, hip
region, wrist, and whole body (Table 1) showed normal
bone mineral density as compared to standards defined
by World Health Organization [17] and no significant
differences between left- and right-sided extremities. Stan-
dard HR-pQCT of the radius and tibia (Table 2) revealed
normal geometry, volumetric bone mineral density, and
microarchitecture, and most parameters do not differ sig-
nificantly from age- and gender-matched normal material
[18]. Again, no significant differences between the two
sides were found. Biochemical evaluation was normal
with hemoglobin 8.9 mmol/L (8.3–10.5 mmol/L), 25-OH
vitamin D 79 nmol/L (50–160 nmol/L), thyroid-stimulat-
ing hormone 1.1 103 IU/L (0.5–4.3 103 IU/L), follicle-
stimulating hormone 6.1 IU/L (1.1–7.9 IU/L), luteinizing
hormone 6.8 IU/L (1.5–11 IU/L), sex hormone-binding
globulin 63.2 nmol/L (13–55 nmol/L), and testosterone
23.5 nmol/L (8.40–30.0 nmol/L).
Discussion
We present a novel synonymous mutation in COL1A2
possibly affecting correct mRNA splicing associated with
OI Sillence type IIA and parental mosaicism for the
mutation, detected by NGS. We report normal bone mor-
phology in the mosaic father, evaluated by DXA scan and
HR-pQCT. The asymmetry in body composition with
slightly reduced size of left-sided extremities in the father
is unlikely to result from the OI mosaicism as this phe-
nomenon may be due to a number of factors [19] and is
not a distinctive feature of OI.
The incidence of mosaicism is most likely highly
underestimated [20]. Low-grade mosaicism is very diffi-
cult to detect by the previous traditional Sanger sequenc-
ing. Although NGS provides a new diagnostic tool for
identifying genetic mosaicism, it can easily be missed as
biased allele calls are filtered out in the bioinformatic
workflow. Revisions of current diagnostic laboratory pro-
tocols are needed in order to increase the detection rate
of mosaic cases [21]. An unknown proportion of muta-
tions categorized as de novo may in fact result from
unrecognized parental mosaicism [20]. Asymptomatic
parental somatic mosaicism has recently been identified
by NGS and reported for a number of rare diseases such
as Alport syndrome, tuberous sclerosis, and Dravet syn-
drome [22–25].
Figure 3. Sanger sequence of c. 1863G>A in COL1A2. A. Fetal
sequence, B. Paternal sequence depicting the mosaicism nature.
Unfortunately, the quality of this image cannot be improved as the
original file is of the same quality.
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Genomic mosaicism results from postzygotic events
occurring predominantly in early embryogenesis but can
arise throughout life and results in genetically distinct cell
lines within one individual. During cell division, errors in
chromosome segregation or DNA replication occur and
may lead to aneuploidy, copy number variations, genome
rearrangements, repeat expansions, microsatellite instabili-
ties, or single-nucleotide variations [26]. Selection against
the mutation can occur and the clinical manifestations
can range from none or minimal to a segmental or severe
generalized effect [27]. The selection pressure is tissue-
dependent as a mutation can be strongly selected against
in tissues in which the gene product is essential to cell
function, whereas the same mutation is tolerated in other
somatic cells [27]. Individuals with mosaicism for
(A) (B)
Figure 4. Reduced size of left-sided extremities of the male patient with OI mosaicism. A. The left thumb is smaller than the right thumb. B. The
left foot is smaller than the right foot.
Table 1. T-scores and Z-scores evaluated by dual energy X-ray
absorptiometry (DXA) scan.
Left side (SD) Right side (SD)
Lumbar spine, total BMD, T-score 0.7 0.7
Lumbar spine, total BMD, Z-score 0.7 0.7
Hip, total BMD, T-score 0.5 0.1
Hip, total BMD, Z-score 0.6 0.2
Wrist, total BMD, T-score 2.0 1.1
Wrist, total BMD, Z-score 1.9 1.0
Whole body scan, total BMD, T-score 0.4 0.4
Whole body scan, total BMD, Z-score 0.5 0.5
The T-score, in units of standard deviation (SD), indicates the standard
deviation from the normal values of a healthy 30 years old of the
same sex. The Z-score, in units of standard deviation (SD), indicates
the standard deviation from the normal values of an age-matched
person of the same sex. According to definitions defined by the World
Health Organization a T-score of 1.0 and above indicates normal
bone density, T-score between 1.0 and 2.5 indicates osteopenia,
and a T-score 2.5 and lower indicates osteoporosis in men aged
more than 50 years [17]. BMD, bone mineral density.
Table 2. Geometry, volumetric bone mineral density, and microarchi-
tecture evaluated by high-resolution peripheral quantitative computed
tomography (HR-pQCT).
Left side Right side
Radius
Cortical bone area (mm2) (75 mm2) 75.9 77.6
Cortical thickness (mm) (1.02 mm) 1.07 1.00
Cortical bone density (mg/cm3) (873 mg/cm3) 926.1 904.8
Trabecular bone density (mg/cm3)
(199 mg/cm3)
219.5 212.1
Trabecular BV/TV (%) (16.5%) 18.3 17.7
Trabecular bone area (mm2) (278 mm2) 195.3 256.2
Trabecular number (per mm) (2.06/mm) 1.78 2.12
Trabecular thickness (mm) (0.080 mm) 0.103 0.083
Trabecular spacing (mm) (0.406 mm) 0.460 0.389
Tibia
Cortical bone area (mm2) (160 mm2) 199.7 192.7
Cortical thickness (mm) (1.31 mm) 1.99 1.83
Cortical bone density (mg/cm3) (876 mg/cm3) 928.8 909.2
Trabecular bone density (mg/cm3)
(218 mg/cm3)
262.5 269.9
Trabecular BV/TV (%) (18.1%) 21.9 22.5
Trabecular bone area (mm2) (737 mm2) 439.1 504.3
Trabecular number (per mm) (2.20/mm) 2.06 2.10
Trabecular thickness (mm) (0.083 mm) 0.106 0.107
Trabecular spacing (mm) (0.362 mm) 0.379 0.369
Normal values [18] in parentheses. BV/TV, bone volume per tissue
volume.
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autosomal dominant OI are often asymptomatic or pre-
sent with subtle clinical manifestations and are only iden-
tified when having a second child with the condition. A
negative selection process in tissues where collagen is of
great importance may be an explanation for the lack of a
recognized phenotype [12]. This highlights the need for
sensitive methods like NGS and suggests that more than
one tissue should be examined.
Osteoporosis develops in the majority of patients with
complete OI, and analyses of bone histomorphometry have
revealed increased bone formation and increased bone
resorption with a net effect of a small progressive bone loss
[4]. Altered bone microstructure and bone geometry, eval-
uated by HR-pQCT, has been reported in patients with OI
types I, III, and IV [28, 29]. However, in two mosaic carri-
ers, normal skeletal growth, bone density, and bone histol-
ogy were found in spite of 40–75% burden of osteoblasts
heterozygous for a COL1A1 mutation [30], which is con-
cordant with our findings.
In conclusion, we report a family affected by two cases
of fetal OI, Sillence type IIA, as a result of parental
mosaicism for a previously unreported synonymous
mutation in the COL1A2 gene. The mosaic father was
clinically unaffected, and evaluation of bone morphology
by DXA scan and HR-pQCT revealed normal bone struc-
ture. As collagen most likely has no functional impor-
tance in spermatocytes, no negative selection pressure
exists and the risk of OI pregnancies is related to the pro-
portion of germ cells with the mutation. A surprisingly
large proportion of assumed de novo mutations may in
fact be related to low-grade parental mosaicism.
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Figure S1. High-resolution peripheral quantitative com-
puted tomography (HR-pQCT) scan images. A. left
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Figure S2. High-resolution peripheral quantitative com-
puted tomography (HR-pQCT) scan images. A. left tibia.
B. Right tibia.
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